



# Sonnenberg & Company, CPAs

A Professional Corporation

5190 Governor Drive, Suite 201, San Diego, California 92122

Phone: (858) 457-5252 • (800) 464-4HOA • Fax: (858) 457-2211 • (800) 303-4FAX



Leonard C. Sonnenberg, CPA

## AUTISM RESEARCH INSTITUTE Audited Financial Statements Year Ended December 31, 2024

	CONTENTS	<u>Page</u>
Independent Auditor's Report		1-2
Financial Statements		
Statement of Financial Position		3
Statement of Activities		4
Statement of Functional Expenses		5
Statement of Cash Flows		6
Notes to Financial Statements		7-14



# Sonnenberg & Company, CPAs

A Professional Corporation

5190 Governor Drive, Suite 201, San Diego, California 92122

Phone: (858) 457-5252 • (800) 464-4HOA • Fax: (858) 457-2211 • (800) 303-4FAX



Leonard C. Sonnenberg, CPA

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of  
**AUTISM RESEARCH INSTITUTE**

### **Opinion**

We have audited the accompanying financial statements of Autism Research Institute (ARI, a nonprofit organization), which comprise the statement of financial position as of December 31, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ARI as of December 31, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

### **Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of ARI and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about ARI's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of ARI's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about ARI's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

**Report on Summarized Comparative Information**

We have previously audited ARI's 2023 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated March 15, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2023, is consistent, in all material respects, with the audited financial statements from which it has been derived.



April 7, 2025

Sonnenberg & Company, CPAs

**AUTISM RESEARCH INSTITUTE**  
Statement of Financial Position  
December 31, 2024  
(With Comparative Information for December 31, 2023)

ASSETS	<u>2024</u>	<u>2023</u>
Cash	\$ 1,143,476	\$ 281,218
Restricted cash	-	21,162
Contributions receivable	1,044,275	50,000
Prepaid expenses	-	26,906
Investments	3,812,505	4,345,041
Property & equipment, net	<u>15,551</u>	<u>16,453</u>
Total assets	<u>\$ 6,015,807</u>	<u>\$ 4,740,780</u>
LIABILITIES & NET ASSETS		
Liabilities		
Accounts payable	\$ 24,630	\$ 12,759
Payroll liabilities	79,420	51,951
Research grants payable	483,000	-
Total liabilities	<u>587,050</u>	<u>64,710</u>
Net Assets		
Without donor restrictions	5,418,646	4,596,323
With donor restrictions	10,111	79,747
Total net assets	<u>5,428,757</u>	<u>4,676,070</u>
Total liabilities & net assets	<u>\$ 6,015,807</u>	<u>\$ 4,740,780</u>

The accompanying notes are an integral part of the financial statements

**AUTISM RESEARCH INSTITUTE**  
Statement of Activities  
For the Year Ended December 31, 2024  
(With Summarized Comparative Information for the Year Ended December 31, 2023)

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>2024 Totals</u>	<u>2023 Totals</u>
<b>SUPPORT &amp; REVENUE</b>				
Contributions	\$ 2,214,024	\$ 1,526	\$ 2,215,550	\$ 1,770,487
Membership dues	3,493		3,493	3,415
Contributed materials			-	478
Interest & dividends, net	115,831		115,831	109,532
Gains on investments	320,745		320,745	367,699
Other income	2,239		2,239	10,186
Net assets released from restrictions	<u>71,162</u>	<u>(71,162)</u>	<u>-</u>	<u>-</u>
 Total support & revenue	 <u>2,727,494</u>	 <u>(69,636)</u>	 <u>2,657,858</u>	 <u>2,261,797</u>
 <b>EXPENSES</b>				
Program Services	1,675,733		1,675,733	1,229,670
Supporting Services				
Management & general	114,962		114,962	134,098
Fundraising	<u>114,476</u>		<u>114,476</u>	<u>80,541</u>
Total supporting services	<u>229,438</u>	<u>-</u>	<u>229,438</u>	<u>214,639</u>
 Total expenses	 <u>1,905,171</u>	 <u>-</u>	 <u>1,905,171</u>	 <u>1,444,309</u>
 Change in net assets	 822,323	 (69,636)	 752,687	 817,488
 Net assets, beginning of year	 <u>4,596,323</u>	 <u>79,747</u>	 <u>4,676,070</u>	 <u>3,858,582</u>
 Net assets, end of year	 <u>\$ 5,418,646</u>	 <u>\$ 10,111</u>	 <u>\$ 5,428,757</u>	 <u>\$ 4,676,070</u>

The accompanying notes are an integral part of the financial statements

**AUTISM RESEARCH INSTITUTE**  
Statement of Functional Expenses  
For the Year Ended December 31, 2024  
(With Summarized Comparative Information for the Year Ended December 31, 2023)

	Program Services	SUPPORTING SERVICES		2024 Totals	2023 Totals
		Management & General	Fundraising		
Advertising & promotion	\$	\$	\$ 2,500	\$ 2,500	\$ 5,375
Accounting		26,775		26,775	23,450
Contract services	67,874	35,743	19,196	122,813	88,863
Depreciation	541	361		902	1,311
Fiscal sponsorship	37,353			37,353	46,680
Insurance		7,302		7,302	7,196
Legal		5,115		5,115	350
Miscellaneous	13,039	1,533		14,572	4,001
Office expenses	18,681	606	909	20,196	23,260
Occupancy	41,620	3,609	2,204	47,433	43,200
Personnel	448,745	32,835	65,670	547,250	473,406
Physicians' training program	17,240			17,240	19,419
Postage & delivery	3,215		2,623	5,838	7,673
Printing & dissemination	19,871		17,080	36,951	24,891
Research grants	808,563			808,563	504,929
Telephone/internet/utilities	10,166	452	678	11,295	10,834
Think tanks/conferences	89,363			89,363	72,143
Travel	3,545	631	3,616	7,792	29,833
Webinars	21,657			21,657	16,559
Website	74,261			74,261	40,936
Total Expenses	\$ <u>1,675,733</u>	\$ <u>114,962</u>	\$ <u>114,476</u>	\$ <u>1,905,171</u>	\$ <u>1,444,309</u>

The accompanying notes are an integral part of the financial statements

**AUTISM RESEARCH INSTITUTE**  
Statement of Cash Flows  
For the Year Ended December 31, 2024  
(With Comparative Information for the Year Ended December 31, 2023)

	<u>2024</u>	<u>2023</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Change in net assets	\$ 752,687	\$ 817,488
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation	902	1,311
Net investment gains	(320,745)	(367,699)
Changes in operating assets and liabilities		
Contributions receivable	(994,275)	(50,000)
Prepaid expenses	26,906	(20,638)
Accounts payable	11,871	31
Payroll liabilities	27,469	3,451
Research grants payable	483,000	(88,928)
Net cash provided by (used in) operating activities	<u>(12,185)</u>	<u>295,016</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Sale of investments	1,834,112	596,502
Purchase of investments	(865,000)	(1,432,000)
Reinvestment of interest & dividends	(115,831)	(109,532)
Net cash provided by (used in) investing activities	<u>853,281</u>	<u>(945,030)</u>
Net increase (decrease) in cash & restricted cash	841,096	(650,014)
Cash & restricted cash at beginning of year	<u>302,380</u>	<u>952,394</u>
Cash & restricted cash at end of year	<u>\$ 1,143,476</u>	<u>\$ 302,380</u>
Cash	\$ 1,143,476	\$ 281,218
Restricted cash	<u>-</u>	<u>21,162</u>
Total cash & restricted cash	<u>\$ 1,143,476</u>	<u>\$ 302,380</u>

The accompanying notes are an integral part of the financial statements

## AUTISM RESEARCH INSTITUTE

Notes to Financial Statements  
Year Ended December 31, 2024

### Note 1. Nature of Organization

The Autism Research Institute (ARI), a non-profit organization, is the hub of a worldwide network of parents and professionals concerned with autism. ARI was founded in 1967 to conduct and foster scientific research designed to improve the methods of diagnosing, treating, and preventing autism. This is accomplished through ARI's mission to support the health and well-being of people affected by autism through innovative, impactful research and education. ARI's programs include the following activities:

- Funding, conducting and facilitating cutting-edge research on underlying cause(s) and effective treatments of autism.
- Maintaining autism.org website, that provides medical, biomedical, nutritional, and educational information on autism.
- Maintaining the ARI data bank, one of the world's largest, which contains over 42,000 detailed case histories of autism from more than 60 countries.
- Collaborating with the National Institute of Child Health and Human Development Brain and Tissue Bank and Massachusetts General Hospital gastrointestinal tissue bank to provide research material for scientists investigating the systemic causes and effects of autism.
- Informing the medical community about best-practice treatments. ARI offers, in joint-providership with the Cleveland Clinic, complimentary *AMA PRA Category1 Credit*<sup>™</sup> to physicians. Connecting physicians to improved standards of care is crucial to amplifying understanding of the medical nature of the disorder.
- Producing free online webcasts focused on cutting-edge research and evidence-based interventions, with nearly 1.2 million views on YouTube.
- Publishing several e-newsletters with more than 140,000 subscribers and a quarterly science newsletter, *Autism Research Review International*, in print and online.
- Facilitating a worldwide network of parents, scientists, and practitioners involved in identifying and exploring evidence-based treatment avenues.
- Sponsoring international and regional multidisciplinary think tanks involving researchers and experienced clinicians.
- Running a toll-free telephone resource line. This service responds to questions from individuals in the autism community.
- Translating materials, live webinars, and recorded webinars into 25 different languages.
- Investigating accurate methods to diagnose autism and the relationship of those methods to treatment efficacy.

ARI is supported primarily by contributions.

### Note 2. Summary of Significant Accounting Policies

Basis of Financial Presentation: The accompanying financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

**AUTISM RESEARCH INSTITUTE**  
Notes to Financial Statements  
Year Ended December 31, 2024

**Note 2.      Summary of Significant Accounting Policies, continued**

*Net Assets:* Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

*Net assets without donor restrictions* - Net assets available for use in general operations and not subject to donor (or certain grantor) restrictions.

*Net assets with donor restrictions* - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity.

Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

*Cash and Cash Equivalents:* Cash and cash equivalents consist of cash and other highly liquid investments with an original maturity of three months or less when purchased. ARI had no cash equivalents as of December 31, 2024. Cash and cash equivalents that are managed as part of investments are reported within investments, as these funds are not used for daily operating needs. These are not considered cash or cash equivalents for purposes of the statement of cash flows.

*Contributions receivable:* Contributions receivable are unconditional promises to make future gifts. ARI recognizes a receivable and contribution revenue at the time the promise is made by the donor if it is verifiable, measurable, and probable of collection. The allowance for uncollectable contributions receivable, if any, is established based on factors such as historical experience and the age of the account balances. All outstanding balances at year end are analyzed for collectability through a review of specific accounts. Based on that analysis, management has determined that no allowance for uncollectable accounts should be established as of December 31, 2024.

*Fair Value Measurements:* ARI measures fair value at the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. Authoritative guidance establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values, requiring that assets and liabilities carried at fair value be classified and disclosed in one of the three levels.

**AUTISM RESEARCH INSTITUTE**  
Notes to Financial Statements  
Year Ended December 31, 2024

**Note 2.      Summary of Significant Accounting Policies, continued**

These levels are:

Level 1: Quoted prices in active markets for identical securities.

Level 2: Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayments, spreads, credit risk, etc.).

Level 3: Significant unobservable inputs (including ARI's own assumptions in determining the fair value of investments).

The valuations of ARI's investments according to the fair value hierarchy are all Level 1.

Investments: Investment purchases are recorded at cost, or if donated, at fair value on the date of donation. Thereafter, investments are reported at fair value based on quoted market prices in active markets. Investment income, comprised of interest and dividends, is reported net of related investment expenses. Realized and unrealized gains and losses on investments, in total, are reported separately from net investment income in the statement of activities.

Investments are exposed to various risks such as significant world events, interest rates, credit, and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the fair value of investments will occur in the near term and that such changes could materially affect the amounts reported in the statement of financial position. Investments are subject to a formal investments policy, which provides for diversification and oversight.

Property and Equipment: Acquisitions of property and equipment in excess of \$2,000 and expenditures for repairs, maintenance, renewals, and betterments that materially prolong the useful lives of assets are capitalized. The costs of maintenance and repairs that do not improve or extend the useful lives of the respective assets are expensed. Property and equipment are carried at cost or, if donated, at the approximate fair value at the date of donation. Depreciation expense for the year ended December 31, 2024 was \$902.

Compensated Absences: Unpaid employee leave benefits are recognized as liabilities of ARI. The accrued vacation liability of \$8,580 is included in payroll liabilities in the statement of financial position as of December 31, 2024.

Revenue Recognition: Contributions are recognized when the donor makes a promise to give to ARI that is, in substance, unconditional. Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not recognized until the conditions on which they depend have been substantially met. Membership dues are recognized over the membership period.

**AUTISM RESEARCH INSTITUTE**  
Notes to Financial Statements  
Year Ended December 31, 2024

**Note 2. Summary of Significant Accounting Policies, continued**

*Contributed Nonfinancial Assets:* The estimated fair value of contributed goods and professional services is recorded in the financial statements. Contributed goods are recorded at fair value at the date of donation. Contributed professional services are recognized in the financial statements if the services create nonfinancial assets, require specialized skills, provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. ARI presents contributed nonfinancial assets in accordance with Accounting Standards Update 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*.

ARI receives contributed volunteer services which have not been reflected in the accompanying financial statements because such services do not meet recognition criteria prescribed by accounting principles generally accepted in the United States of America.

*Leases:* ARI accounts for leases in accordance with FASB ASC 842. An arrangement is a lease if the arrangement conveys a right to direct the use of, and obtain substantially all of the economic benefits from, the use of an asset for a period of time in exchange for consideration. ARI determines if an arrangement is or contains a lease at inception. ARI recognizes operating lease ROU assets and related operating lease liabilities in the statement of financial position. A lease liability is measured based on the present value of its future lease payments.

ARI does not apply the recognition requirements of this standard to short-term leases. The lease payments for leases with original terms of twelve months or less are recognized on the straight-line basis. Leases of one month or less are not included in short-term lease costs.

*Research Grants Payable:* Unconditional grants are recorded as expenses when awarded by ARI and the recipients are notified. Grants that are subject to conditions are recorded when the conditions have been substantially met. Unconditional grants authorized but unpaid at year end are reported as liabilities in the statement of financial position. Research grants payable in the amount of \$483,000 at December 31, 2024 were expected to be paid within one year.

*Functional Allocation of Expenses:* The costs of providing various services and other activities have been summarized on a functional basis in the statement of activities. The statement of functional expenses presents the natural classification detail of expenses by function. Directly identifiable expenses are charged to programs and supporting services benefited. Management and general expenses include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of ARI. The financial statements report certain categories of expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Personnel and related expenses are allocated based on employee time attributed to program activities or supporting services. Overhead costs, which include office expenses, occupancy, telephone, internet, and utilities, are allocated based on the weighted average of personnel costs attributed to program activities or supporting services.

## AUTISM RESEARCH INSTITUTE

Notes to Financial Statements  
Year Ended December 31, 2024

### Note 2. Summary of Significant Accounting Policies, continued

*Comparative Financial Information:* The accompanying financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with ARI's audited financial statements for the year ended December 31, 2023, from which the summarized information was derived. Certain reclassifications of the prior year's amounts have been made to maintain consistency between periods presented.

*Estimates:* The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates under different assumptions or conditions.

### Note 3. Income Tax Status

ARI is exempt from federal and state income taxes under Section 501(c)(3) of the Internal Revenue Code and Section 23701(d) of the California State Revenue and Taxation Code. ARI qualifies for the charitable contribution deduction under IRC Sections 170(b)(1)(A)(vi) and (viii) and is annually required to file a Return of Organization Exempt from Income Tax (Form 990) with the IRS. In addition, it is subject to income tax on net income that is derived from business activities that are unrelated to its exempt purposes. Management has determined that ARI is not subject to unrelated business income tax and has not filed an Exempt Organization Business Income Tax Return (Form 990-T) with the IRS for the year ended December 31, 2024. Management has evaluated its tax positions and related income tax contingencies and does not believe that any material uncertain tax positions exist.

### Note 4. Investments

At December 31, 2024, investments consisted of the following:

Cash and cash equivalents held for long-term investments	\$ 47,694
Mutual funds	53,170
Equities	2,155,712
Fixed income & preferreds	1,333,297
Alternatives	222,632
	<u>\$ 3,812,505</u>

**AUTISM RESEARCH INSTITUTE**  
Notes to Financial Statements  
Year Ended December 31, 2024

**Note 5.      Liquidity and Availability of Financial Assets**

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

Financial assets at year end:	
Cash	\$ 1,143,476
Contributions receivable	1,044,275
Investments	<u>3,812,505</u>
Total financial assets	6,000,256
Funds subject to donor-imposed restrictions	<u>(10,111)</u>
Financial assets available to meet general expenditures within one year	<u><u>\$ 5,990,145</u></u>

ARI receives contributions with donor restrictions to be used in accordance with the associated purpose restrictions. ARI must maintain sufficient resources to meet those responsibilities to its donors. Thus, financial assets may not be available for general expenditures within one year. As part of ARI's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

**Note 6.      Concentrations**

Financial instruments that potentially subject ARI to concentrations of credit risk consist principally of cash deposits. Cash balances at banks are insured by the Federal Deposit Insurance Corporation (FDIC) up to \$250,000. As of December 31, 2024, ARI's uninsured cash balance was \$551,572. ARI has historically not experienced any losses on its cash balances in relation to FDIC insurance limits.

For the year ended December 31, 2024, 51%, or \$1,123,202 of ARI's contribution revenue came from one donor. The receivable from this donor was \$1,028,402, which accounted for 98% of contributions receivable as of December 31, 2024 (Note 14).

**Note 7.      Property and Equipment**

Property and equipment consist of the following as of December 31, 2024:

Leasehold improvements	\$ 18,018
Domain name	<u>10,000</u>
	28,018
Less: accumulated depreciation	<u>(12,467)</u>
Property and equipment, net	<u><u>\$ 15,551</u></u>

**AUTISM RESEARCH INSTITUTE**  
Notes to Financial Statements  
Year Ended December 31, 2024

**Note 8. Net Assets With Donor Restrictions**

Net assets with donor restrictions are restricted for the following purposes as of December 31, 2024:

Oxalate study	\$ 8,585
Think Tanks/research	185
Continuing education	1,341
	\$ 10,111

Net assets in the amount of \$71,162 were released from donor restrictions for the year ended December 31, 2024 by incurring expenses satisfying the restricted purpose of grants for research.

**Note 9. Fiscal Sponsorship Agreement**

ARI acts as a fiscal sponsor for Autism/Asperger’s Research Program at Arizona State University (Program). In accordance with the November 2015 agreement, ARI receives donations on behalf of the Program, including proceeds of a fundraising event organized by the Program, “Zoowalk for Autism Research”. The funds are held in a separate checking account and disbursed for walk related expenses and research grants at ARI’s discretion upon request of the Program. The agreement was terminated during the year ended December 31, 2024.

**Note 10. Operating Lease**

ARI leases its office space at 4182, 4184, 4186, and 4186 1/2 Adams Avenue under a month-to-month operating lease agreement. Total rent expense was \$36,733 for the year ended December 31, 2024.

**Note 11. Service Contracts/Related Party Transactions**

Under an agreement for the physicians’ training webcast program with The Cleveland Clinic Foundation (CCF), ARI reimburses CCF for expenses related to the production of training videos. Physicians receive continuing medical education credit for viewing online videos which are available on the Cleveland Clinic Center for Continuing Education website. ARI paid \$15,990 to CCF in 2024 under the August 30, 2023 agreement for Series 7: *Current Perspectives on Autism*. ARI’s remaining future obligations under the agreement as of December 31, 2024 were \$10,660. The obligations are to be fulfilled in accordance with the budget as the work is completed.

ARI paid \$7,250 during the year ended December 31, 2024 to a Board Officer for developing curriculum and moderating several continuing education webcasts for licensed medical professionals. The Board Officer also serves as Activity Director for the physicians’ training webcast program.

## **AUTISM RESEARCH INSTITUTE**

Notes to Financial Statements  
Year Ended December 31, 2024

### **Note 12. Retirement Benefits**

ARI maintains 403(b)(7) retirement plan for its employees. Employees may defer part of their compensation each year up to the maximum amount allowed by the Internal Revenue Code. No employer contributions to the plan were made during the year ended December 31, 2024.

### **Note 13. Contract Commitments**

On October 3, 2024, ARI entered into a contract for hotel rooms, meeting space, and food and beverage services for the May 2025 Scientific Think Tank meeting. In accordance with the contract, the cancellation fee ranges from \$9,710 if the contract is cancelled prior to December 7, 2024 to \$33,016 if the contract is cancelled after March 8, 2025.

On October 1, 2024, ARI entered into a contract for audiovisual equipment and services for the May 2025 Scientific Think Tank meeting. In accordance with the contract, no cancellation charges apply if the contract is cancelled 30 days or more prior to the event. Cancellation fees range from 50% to 100% of the total anticipated charges of \$20,255 if the contract is cancelled between 29 and less than three days prior to the event.

### **Note 14. The Estate of Ruth P. Cohen Contribution and Subsequent Event**

During the year ended December 31, 2024, ARI was notified that it was chosen by the Executor of the Estate of Ruth P. Cohen as one of the beneficiaries of the remainder of the estate. Two distributions totaling \$94,800 were received during the year ended December 31, 2024. On March 25, 2025, ARI was notified that the final amount of ARI's share of the residuary estate, including additional income, will be \$1,028,402. Therefore, contribution revenue in the amount of \$1,028,402 and corresponding contribution receivable have been recorded as of December 31, 2024.

### **Note 15. Date of Management Review**

ARI's management has evaluated subsequent events through April 7, 2025, the date the financial statements were available to be issued. Except as disclosed in Note 14, management is not aware of any subsequent events that would require adjustments to, or disclosure in, the financial statements.